Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.

JAMA otolaryngology-- head & neck surgery - 1 Jun 2016

Birkeland Andrew C, Yanik Megan, Tillman Brittny N, Scott Megan V, Foltin Susan K, Mann Jacqueline E, Michmerhuizen Nicole L, Ludwig Megan L, Sandelski Morgan M, Komarck Christine M, Carey Thomas E, Prince Mark E P, Bradford Carol R, McHugh Jonathan B, Spector Matthew E, Brenner J Chad

Abstract excerpt

IMPORTANCE: ERBB2 (formerly HER2) is an important drug target in breast cancer, where anti-ERBB2 therapy has been shown to lead to improvements in disease recurrence and overall survival. ERBB2 status in head and neck squamous cell carcinoma (HNSCC) has not been well studied. Identification of ERBB2-positive tumors and characterization of response to ERBB2 therapy could lead to targeted treatment options in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxybutyrates

Share to Laryngeal Neoplasms

Share to Mouth Neoplasms

Share to Purines

Share to Receptor, ErbB-2

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 27077364
DOI: 10.1001/jamaoto.2016.0335
PMCID: PMC4911238

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.PMID 27077364Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas.Semantic proximity Read ↗

Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid Tumors.Semantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

ERBB2 mutation: A promising target in non-squamous cervical cancer.Semantic proximity Read ↗

Molecular profiling of head and neck squamous cell carcinoma.Semantic proximity Read ↗

Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.Semantic proximity Read ↗

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.Semantic proximity Read ↗

Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid CancersSemantic proximity Read ↗

Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.Semantic proximity Read ↗

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.